thymine has been researched along with Thyroid Neoplasms in 4 studies
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, Y | 1 |
| Xing, M | 2 |
| Mambo, E | 1 |
| Guo, Z | 1 |
| Wu, G | 2 |
| Trink, B | 2 |
| Beller, U | 1 |
| Westra, WH | 1 |
| Ladenson, PW | 1 |
| Sidransky, D | 1 |
| Hayashida, N | 1 |
| Namba, H | 1 |
| Kumagai, A | 1 |
| Hayashi, T | 1 |
| Ohtsuru, A | 1 |
| Ito, M | 1 |
| Saenko, VA | 1 |
| Maeda, S | 1 |
| Kanematsu, T | 1 |
| Yamashita, S | 1 |
| Vasko, V | 1 |
| Hu, S | 1 |
| Xing, JC | 1 |
| Larin, A | 1 |
| Savchenko, V | 1 |
| Sapio, MR | 1 |
| Guerra, A | 1 |
| Posca, D | 1 |
| Limone, PP | 1 |
| Deandrea, M | 1 |
| Motta, M | 1 |
| Troncone, G | 1 |
| Caleo, A | 1 |
| Vallefuoco, P | 1 |
| Rossi, G | 1 |
| Fenzi, G | 1 |
| Vitale, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459] | Phase 1 | 57 participants (Actual) | Interventional | 2004-11-02 | Completed | ||
| A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215] | Phase 2 | 55 participants (Actual) | Interventional | 2006-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| BAY 43-9006 + Bevacizumab | 54 |
Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Weeks (Mean) |
|---|---|
| BAY 43-9006 + Bevacizumab | 26 |
Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| BAY 43-9006 + Bevacizumab | 0 | 19 | 21 | 60 |
4 other studies available for thymine and Thyroid Neoplasms
| Article | Year |
|---|---|
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells.
Topics: Adenine; Base Sequence; Biopsy, Fine-Needle; Genetic Techniques; Humans; Mutation; Neoplasm Staging; | 2004 |
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
Topics: Adenine; Adolescent; Adult; Aged; Carcinoma, Papillary; Female; Gene Frequency; Humans; Lymphatic Me | 2005 |
Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma.
Topics: Adenine; Adenocarcinoma, Papillary; Amino Acid Substitution; Biopsy, Fine-Needle; Galectin 3; Humans | 2007 |